Notably, cells deficient in PTEN benefit from a combination treatment with IR and olaparib or BMN673, which may assist the design of individualized strategies for GBM therapy, taking advantage of the highly localized application of IR that reduces effects on normal tissues. The gene discussed is PTEN; the disease is glioblastoma.